companydata.dkInnosurge Biologics A/S: Financial statements 2024
CVR: 38768964
Innosurge Biologics A/S (CVR 38768964) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 2,444,975 and a net result of DKK 251,617 compared with DKK 406,817 the year before. That is an increase of 17.7% compared with the year before. Equity amounted to DKK 1,984,503. The solvency ratio was 55%. The company had 2 employees in the financial year.
- Gross Profit
- 2,444,975 kr.
- Profit/Loss
- 251,617 kr.
- Equity
- 1,984,503 kr.
- Total Assets
- 3,610,840 kr.
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 2.4 mio. | 252 t. | 2 mio. | 2 |
| 2023 | - | 2.1 mio. | 407 t. | 1.7 mio. | 2 |
| 2022 | - | 2.2 mio. | 490 t. | 1.3 mio. | 3 |
| 2021 | - | 993 t. | -613 t. | 836 t. | 3 |
| 2020 | - | -695 t. | -2.6 mio. | 1.4 mio. | 3 |
How creditworthy is Innosurge Biologics A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2024
Innosurge Biologics A/S has published its annual report for 2023. Gross profit came to DKK 2,077,814, and the net result was DKK 406,817.
About Innosurge Biologics A/S
Innosurge Biologics A/S is a Danish company of the type Aktieselskab based in Randers NV, founded in 2017. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The management consists of Peter Møller Lassen. The company is owned by CMA HOLDING RANDERS ApS. The company has 1 employee. In 2025, the company reported a gross profit of DKK 4,455,235 and a net result of DKK 1,662,593 compared with DKK 251,617 the year before. Equity amounted to DKK 2,897,096.